Strong Industry Position As a leader in in vivo antibody discovery and a division of Twist Bioscience, Abveris has established itself as a key player in the biotechnology research space, opening opportunities for partnerships with biopharmaceutical companies seeking advanced antibody solutions.

Notable Collaborations Recent partnerships with companies like Enzolytics Inc and multi-year collaborations with Prometheus Biosciences highlight Abveris’s active engagement in therapeutic antibody development, presenting potential avenues for joint ventures or contract research services.

Award-winning Workplace Repeated recognition as one of the best places to work signals a high-performing, motivated team, which can be leveraged to build relationships with their R&D and scientific staff for potential collaborations or client referrals.

Recent Funding & Acquisition The acquisition by Twist Bioscience for 190 million dollars and ongoing revenue streams suggest financial stability and growth potential, making Abveris a reliable partner for large-scale biotech partnerships and joint ventures.

Innovation in Viral Research Development and public release of SARS-CoV-2 spike protein antibodies demonstrate expertise in infectious disease and virus target discovery, indicating opportunities to explore collaborations in vaccine development or antiviral therapeutics.